

Press Release

October 18th 2017

LYSOGENE



Lysogene Announces Company Presentations at Upcoming Scientific Conferences

Paris, France and Cambridge, MA, US — October 18th 2017, 6 pm CET — Lysogene (FR0013233475 – LYS), a leading, biopharmaceutical company pioneering gene therapy technologies to treat central nervous system diseases, today announced that it will be participating in and presenting at several scientific events in the upcoming weeks. A detailed list of the October and November events is as follows:

- [25th Anniversary Congress of the European Society of Gene and Cell Therapy \(ESGCT\)](#)
Date: Thursday, October 19, 2017
Time: 18.45-20.15 pm European Central Time
Location: The bcc Berlin, Germany
- [Gene Therapy for Rare Disorders Europe](#)
Date: Thursday, November 2, 2017
Time: 3:00 pm Greenwich Mean Time
Location: Hilton London Olympia, London, UK
- [Europabio Patients Bio-Forum: “How to make the most of European Reference Networks \(ERNs\)”](#)
Date: Thursday, November 9, 2017
Time: 13:30 pm European Central Time
Location: EuropaBio, Brussels, Belgium
- [Advanced Therapies – Opportunities and Challenges](#)
Date: Tuesday, November 14, 2017
Time: 1:00 pm Greenwich Mean Time
Location: BMA House, London, UK
- [World Orphan Drug Congress](#)
Date: Wednesday, November 15, 2017
Time: 4:05 pm European Central Time
Location: Fairmont Rey Juan Carlos, Barcelona, Spain
- [RARE les 5èmes rencontres des maladies rares](#)
Date: Friday, November 20, 2017
Time: 5:30 pm European Central Time

Location: Cité des Sciences et de l'Industrie, Paris, France

About Lysogene

Lysogene (www.lysogene.com) is a global biopharma leader in orphan CNS disease research and development. Lysogene has generated five non-cumulative years of clinical safety data to show the efficiency of a direct delivery route to the CNS with its initial gene therapy trial for MPS IIIA. Lysogene has recently completed the enrollment for the first multi-national observational study in MPS IIIA which will function as the non-concurrent control for the first pivotal trial for MPS IIIA in H1 2018. Lysogene also plans a clinical trial for GM1 Gangliosidosis for 2019. Lysogene has obtained orphan drug designation from the EMA and FDA and rare pediatric designation by the FDA for both programs.

Lysogene is listed on the Euronext regulated market in Paris (ISIN code: FR0013233475).

For more information: www.lysogene.com.

Contacts

Media:

Europe

Annie-Florence Loyer
NewCap
afloyer@newcap.fr
+ 33 6 88 20 35 59
+ 33 1 44 71 00 12

Investors:

Chris Maggos
LifeSci Advisors
chris@lifesciadvisors.com
+41 79 367 6254

North America

Marion Janic
RooneyPartners
mjanic@rooneyco.com
+ 1 (212) 223-4017